Publications by authors named "Alison Dunning"

Purpose: Overlapping genes are involved with rheumatoid arthritis (RA) and DNA repair pathways. Therefore, we hypothesised that patients with a high polygenic risk score (PRS) for RA will have an increased risk of radiotherapy (RT) toxicity given the involvement of DNA repair.

Methods: Primary analysis was performed on 1494 prostate cancer, 483 lung cancer and 1820 breast cancer patients assessed for development of RT toxicity in the REQUITE study.

View Article and Find Full Text PDF

Background: The 313-variant polygenic risk score (PRS) provides a promising tool for clinical breast cancer risk prediction. However, evaluation of the PRS across different European populations which could influence risk estimation has not been performed.

Methods: We explored the distribution of PRS across European populations using genotype data from 94,072 females without breast cancer diagnosis, of European-ancestry from 21 countries participating in the Breast Cancer Association Consortium (BCAC) and 223,316 females without breast cancer diagnosis from the UK Biobank.

View Article and Find Full Text PDF
Article Synopsis
  • Known genetic risk factors account for about one-third of familial endometrial cancer cases, but the link between rare germline copy number variants (CNVs) and cancer risk is not well understood.
  • A study analyzed DNA from over 4,000 endometrial cancer patients and nearly 18,000 controls, finding that the cancer group had a significantly higher number of CNVs.
  • The research identified 141 gene loci potentially related to endometrial cancer risk, highlighting a specific area (16p11.2) with recurrent deletions that could help further investigations into genetic susceptibility.
View Article and Find Full Text PDF

Purpose: Most breast biopsies are diagnosed as benign breast disease (BBD), with 1.5- to fourfold increased breast cancer (BC) risk. Apart from pathologic diagnoses of atypical hyperplasia, few factors aid in BC risk assessment of these patients.

View Article and Find Full Text PDF
Article Synopsis
  • Clinical genetic testing helps find cancer risks by identifying gene changes, but some of these changes are confusing because we don't know what they mean (called VUS).
  • Researchers studied a huge number of breast cancer patients and healthy people to understand these confusing gene changes better.
  • They found that their method of analyzing data closely matches what other experts say about which gene changes are harmless or harmful, giving more information about 785 unclear changes.
View Article and Find Full Text PDF
Article Synopsis
  • * Analysis of data from over 55,000 breast cancer patients showed that co-observation of variants in BRCA1, BRCA2, and PALB2 with other breast cancer genes occurred less frequently than expected, suggesting a potential correlation with pathogenicity.
  • * The findings indicate that identifying a variant of uncertain significance alongside a known pathogenic variant supports evidence against the variant's pathogenicity, which could improve variant classification in clinical settings and for other genetic conditions.
View Article and Find Full Text PDF
Article Synopsis
  • Scientists looked at the timing of when girls start their periods (called menarche) and how it can affect their health later in life.
  • They studied about 800,000 women and found over a thousand genetic signals that influence when menstruation starts.
  • Some women have a much higher chance of starting their periods too early or too late based on their genetic makeup, suggesting that genes play a big role in this process!
View Article and Find Full Text PDF

Purpose: Mammographic density phenotypes, adjusted for age and body mass index (BMI), are strong predictors of breast cancer risk. BMI is associated with mammographic density measures, but the role of circulating sex hormone concentrations is less clear. We investigated the relationship between BMI, circulating sex hormone concentrations, and mammographic density phenotypes using Mendelian randomization (MR).

View Article and Find Full Text PDF

The 313-variant polygenic risk score (PRS) provides a promising tool for breast cancer risk prediction. However, evaluation of the PRS across different European populations which could influence risk estimation has not been performed. Here, we explored the distribution of PRS across European populations using genotype data from 94,072 females without breast cancer, of European-ancestry from 21 countries participating in the Breast Cancer Association Consortium (BCAC) and 225,105 female participants from the UK Biobank.

View Article and Find Full Text PDF

Background: Clinical management of Asian and pathogenic variants (PV) carriers remains challenging due to imprecise age-specific breast (BC) and ovarian cancer (OC) risks estimates. We aimed to refine these estimates using six multi-ethnic studies in Asia.

Methods: Data were collected on 271 and 301 families from Malaysia and Singapore, ascertained through population/hospital-based case-series (88%) and genetic clinics (12%).

View Article and Find Full Text PDF
Article Synopsis
  • Scientists looked at how certain genes may affect breast cancer in women with African ancestry.
  • They studied 9,241 women with breast cancer and compared them to 10,193 healthy women to find links between the genes and the disease.
  • They found specific gene variations that could increase the risk of breast cancer, especially types of cancer that don't depend on estrogen.
View Article and Find Full Text PDF
Article Synopsis
  • A recent study analyzed genetic data from over 156,000 prostate cancer cases and 788,000 controls from diverse populations, significantly increasing the representation of non-European participants.
  • Researchers identified 187 new genetic risk variants for prostate cancer, bringing the total to 451, enhancing understanding of genetic factors across different ancestries.
  • The developed genetic risk score (GRS) showed varying risk levels for prostate cancer among different ancestry groups, highlighting its potential for better risk assessment, especially in men of African descent.
View Article and Find Full Text PDF

Background: This study was designed to identify common genetic susceptibility and shared genetic variants associated with acute radiation-induced toxicity across 4 cancer types (prostate, head and neck, breast, and lung).

Methods: A genome-wide association study meta-analysis was performed using 19 cohorts totaling 12 042 patients. Acute standardized total average toxicity (STATacute) was modelled using a generalized linear regression model for additive effect of genetic variants, adjusted for demographic and clinical covariates (rSTATacute).

View Article and Find Full Text PDF
Article Synopsis
  • Light-at-night exposure is linked to decreased melatonin production from the pineal gland and is considered a potential risk factor for breast cancer by the IARC.
  • A study of 44,405 women examined the relationship between breast cancer risk and genetic variations (SNPs) associated with melatonin synthesis and signaling, using logistic regression for analysis.
  • Significant findings included 10 SNPs in the TPH2 gene and one in the MAPK8 gene, suggesting that these genetic factors may influence breast cancer risk, particularly in relation to circadian disruptions caused by light exposure at night.
View Article and Find Full Text PDF

Linkage and candidate gene studies have identified several breast cancer susceptibility genes, but the overall contribution of coding variation to breast cancer is unclear. To evaluate the role of rare coding variants more comprehensively, we performed a meta-analysis across three large whole-exome sequencing datasets, containing 26,368 female cases and 217,673 female controls. Burden tests were performed for protein-truncating and rare missense variants in 15,616 and 18,601 genes, respectively.

View Article and Find Full Text PDF
Article Synopsis
  • A genome-wide study explored gene-environment interactions (G×E) to identify variants that could impact breast cancer risk, analyzing data from around 72,285 breast cancer cases and 80,354 controls.
  • Researchers found two specific SNP-risk factor pairs that showed a significant association with breast cancer risk, including variations related to adult height and age at menarche.
  • Overall, the study concluded that G×E interactions contribute minimally to the heritability of breast cancer and don't significantly enhance risk prediction for the disease.
View Article and Find Full Text PDF

Pubertal timing varies considerably and has been associated with a range of health outcomes in later life. To elucidate the underlying biological mechanisms, we performed multi-ancestry genetic analyses in ~800,000 women, identifying 1,080 independent signals associated with age at menarche. Collectively these loci explained 11% of the trait variance in an independent sample, with women at the top and bottom 1% of polygenic risk exhibiting a ~11 and ~14-fold higher risk of delayed and precocious pubertal development, respectively.

View Article and Find Full Text PDF
Article Synopsis
  • Polygenic risk scores (PRSs), derived from genome-wide association studies (GWASs), can enhance breast cancer risk evaluation but are primarily based on European populations.
  • This study analyzed the effectiveness of European-based PRS models in identifying breast cancer risk among Ashkenazi Jewish women in Israel using data from two cohorts.
  • Results indicated that these PRS models successfully identified Ashkenazi Jewish women at high risk for breast cancer, suggesting they could improve risk assessment in this group.
View Article and Find Full Text PDF
Article Synopsis
  • * The study revealed significant variation in the prevalence of four common PTVs across different regions in Europe, with p.Gln1701* being most common in Northern Europe and p.Gly1906Alafs*12 most common in Southern Europe.
  • * Findings suggest that the distribution of rare PTVs is more heterogeneous in Southwestern and Central Europe compared to Northeastern Europe, which will aid in crafting targeted genetic testing for breast cancer in specific European populations.
View Article and Find Full Text PDF

Background And Purpose: Up to a quarter of breast cancer patients treated by surgery and radiotherapy experience clinically significant toxicity. If patients at high risk of adverse effects could be identified at diagnosis, their treatment could be tailored accordingly. This study was designed to identify common single nucleotide polymorphisms (SNPs) associated with toxicity two years following whole breast radiotherapy.

View Article and Find Full Text PDF
Article Synopsis
  • Breast cancer patients with the CHEK2 c.1100delC variant have a heightened risk of developing a second breast cancer (contralateral breast cancer) and generally experience worse survival outcomes compared to those without the variant.
  • A study involving over 82,000 women aimed to evaluate how the CHEK2 variant, radiotherapy, and systemic treatments affect the risk of contralateral breast cancer and breast cancer-specific survival.
  • Findings indicated that while systemic therapy (especially the combination of chemotherapy and endocrine therapy) lowers the risk of contralateral breast cancer, CHEK2 c.1100delC carriers still faced poorer survival rates, suggesting other factors at play beyond the risk of developing a second cancer.*
View Article and Find Full Text PDF
Article Synopsis
  • A study evaluated the PREDICT v 2.2 tool for predicting the prognosis of breast cancer in patients with BRCA1 and BRCA2 gene variants, using data from over 5,400 carriers across two major cancer research consortia.
  • The PREDICT model showed reasonable effectiveness in distinguishing high-mortality groups for estrogen receptor (ER)-negative breast cancer in BRCA1 carriers, while for BRCA2 carriers, its accuracy was lower and fluctuated based on tumor characteristics.
  • The findings suggest that while PREDICT can aid in management of breast cancer patients, adjustments for BRCA2 status and tumor features are necessary to improve prognosis estimates, particularly for ER-positive cases.
View Article and Find Full Text PDF
Article Synopsis
  • - The study investigated the links between genetic variants in breast cancer susceptibility genes (besides BRCA1, BRCA2, and CHEK2) and risks of developing contralateral breast cancer (CBC) and breast cancer-specific survival (BCSS) in 34,401 women of European ancestry who had been diagnosed with breast cancer.
  • - Significant findings revealed that protein-truncating variants (PTVs) and certain missense variants (MSVs) in genes like BRCA1, BRCA2, TP53, CHEK2, and PALB2 were associated with higher CBC risk and negative impacts on BCSS, indicating that these genetic factors play a crucial role in cancer outcomes.
  • - The results showed minimal
View Article and Find Full Text PDF